Full Breakdown
CDC Study Finds 24% Alpha-Gal Antibody Prevalence in Five States
7/3/2026, 10:30:58 PM
CDC Study Finds 24% Alpha-Gal Antibody Prevalence in Five States
The CDC examined 3,000 blood samples collected Nov 2024–Apr 2025 from donors in ten states. About one-quarter of adults in Arkansas, Kentucky, Missouri, Tennessee and Virginia tested positive for alpha-gal antibodies, indicating prior tick exposure.
Background & Context
Alpha-gal syndrome (AGS) is a delayed allergy to mammalian meat, dairy and gelatin triggered when a tick—usually the lone-star tick—injects the carbohydrate galactose-?-1,3-galactose (alpha-gal) into a person. Black-legged, Cayenne and Asian long-horned ticks can also transmit it. The CDC previously estimated up to 450,000 Americans might have AGS, but exact prevalence remains unclear.
Key Data
- Sample size: 3,000 donors.
- Antibody prevalence: 24 % in the five high-risk states.
- Antibodies show exposure, not necessarily clinical AGS.
- Only a minority of antibody-positive people develop symptoms, per CDC guidance.
Why It Matters
A 24 % exposure rate suggests many more individuals could later develop AGS, a lifelong allergy that can trigger severe anaphylaxis hours after red-meat consumption. Warmer winters and expanding deer populations are pushing lone-star ticks northward, potentially raising case numbers beyond current hotspots.
Official Statements & Responses
CDC officials said antibodies alone do not justify testing, recommending testing only for patients with delayed symptoms. They noted AGS is not on the Notifiable Diseases Surveillance System and that a few states require case reporting. The Council of State and Territorial Epidemiologists (CSTE) will review the data for disease-list updates.
Criticism & Opposition
Sharon Forsyth, executive director of the Alpha-Gal Alliance Action Fund, said the lack of national tracking is unacceptable, arguing AGS is among most common vector-borne diseases in the United States yet remains uncounted. Critics say without systematic surveillance, public-health responses cannot match true disease burden.
Conflicting Reports & Gaps
Sources agree antibodies mark tick exposure, but they differ on how many will develop clinical AGS. The CDC’s 450,000-person estimate contrasts with the study’s caution that most antibody-positive individuals stay asymptomatic. No data yet quantify future case growth as tick ranges expand.
Verbatim Quotes
- “We are concerned about overdiagnosis.” — Dr. Eleanor Saunders, University of North Carolina–Chapel Hill
- “mind-boggling,” — Sharon Forsyth, Alpha-Gal Alliance Action Fund
- “There’s no doubt that alpha-gal is one of the most common vector-borne diseases in the United States, yet they’re not counting cases. How insane is that?” — Sharon Forsyth, Alpha-Gal Alliance Action Fund
- “We’re seeing an increase in cases in the Oklahoma region, and northward into the Great Lakes,” — Dr. Scott Commins, University of North Carolina Department of Medicine, Chapel Hill
What’s Next
The CDC will present the findings to CSTE this year for inclusion of AGS on the notifiable disease list. Researchers call for longitudinal studies to measure conversion from antibody presence to symptomatic disease, while health agencies recommend heightened tick-avoidance practices in expanding risk areas.
